RSV Prevention in Infants: Promising Products, But at What Cost?

Affiliations

¹ Sections of Pediatric Infectious Diseases/Epidemiology and General Academic Pediatrics, Department of Pediatrics, University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, Colorado; and Adult and Child Center for Outcomes Research and Delivery Science, Aurora, Colorado.

Editorial

Sean T O'Leary. Pediatrics. 2024.

. 2024 Dec 1;154(6):e2024068261.

doi: 10.1542/peds.2024-068261.

¹ Sections of Pediatric Infectious Diseases/Epidemiology and General Academic Pediatrics, Department of Pediatrics, University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, Colorado; and Adult and Child Center for Outcomes Research and Delivery Science, Aurora, Colorado.

No abstract available

Comment on

Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness.
Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, McMorrow ML, Fleming-Dutra KE, Prill MM, Pike J, Jones JM. Hutton DW, et al. Pediatrics. 2024 Dec 1;154(6):e2024066481. doi: 10.1542/peds.2024-066481. Pediatrics. 2024. PMID: 39582303
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children.
Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, McMorrow ML, Fleming-Dutra KE, Prill MM, Pike J, Jones JM. Hutton DW, et al. Pediatrics. 2024 Dec 1;154(6):e2024066461. doi: 10.1542/peds.2024-066461. Pediatrics. 2024. PMID: 39582316